FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.645,59 +731,00 (+1,24%)
Exagen Inc. (XGN)
| Chiusura precedente | 1,4000 |
| Aperto | 1,4100 |
| Denaro | 1,3800 x 100 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 1,3850 - 1,4128 |
| Intervallo di 52 settimane | 1,3000 - 3,9230 |
| Volume | |
| Media Volume | 37.942 |
| Capitalizzazione | 24,339M |
| Beta (5 anni mensile) | 1,19 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,3400 |
| Prossima data utili | 13 mag 2024 - 17 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 5,50 |
GlobeNewswireExagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting
SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2023, being held November 10-15, 2023, at the San Diego Convention Center in San Diego, California. Below is the list of accepted abstracts, with links to each: Sunday, November 12, 2023 Poster Presentation | Presented by Doruk E
- GlobeNewswire
Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
SAN DIEGO, California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Cantor Fitzgerald Global Healthcare Conference, which takes place September 26-28, 2023, at the InterContinental Barclay Hotel in New York City. John Aballi, Exagen’s President and Chief Executive Officer and Kamal Adawi, Exagen’s Chief Financial Officer, will participate in a panel discussion on Tuesday, September
- GlobeNewswire
Exagen Inc. Reports Strong Second Quarter 2023 Results
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2023. Second Quarter Highlights: Delivered a record 37,749 AVISE® CTD tests in the second quarter, an 8% increase over the second quarter of 2022.Recognized total revenue of $14.1 million for the second quarter, a 26% increase over the first quarter of 2023.Achieved gross margin of 54% in the six months ended J
